Survey results show that clinicians largely disagree about choices for severe asthma treatment, due primarily to a lack of ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

This is especially true for a subtype known as eosinophilic asthma -- asthma that's related to the recruitment and overactivation of white blood cells in the lungs called eosinophils. However ...

Researchers conducted a prospective study to examine the association between serum 25(OH)D levels at the age of 3 years and the risk for the onset of eosinophilic asthma by the age of 6 years ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Pre-treatment disease trajectories in severe asthma impact treatment-related outcomes, according to a study by Johannes Martin Schmid, PhD, and colleagues.

Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...

Treatment for eosinophilic esophagitis often involves collaboration between specialists, but patients face challenges in ...